Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers...
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Ruxolitinib (Jakafi,...
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers...
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers...
DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population...
Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed...
MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-...
Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin...
Myelofibrosis is a hematological malignancy characterized by disrupted production of blood cells and bone marrow scarring; symptoms include severe...
MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia...
DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries...
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukem...
Get content updates to your inbox
Subscribe